What Adrenomed does

Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company founded in 2009 and headquartered in Hennigsdorf near Berlin, Germany. The company is developing enibarcimab (INN, formerly Adrecizumab/HAM8101), a first-in-class non-neutralizing monoclonal antibody that targets Adrenomedullin (ADM), an endogenous vasoprotective peptide regulator of vascular integrity. Its lead indication is septic shock, a life-threatening condition driven by loss of endothelial barrier function with reported mortality of 30–50% and no approved causative therapy. Adrenomed applies a biomarker-guided precision medicine approach, using bio-ADM (biologically active Adrenomedullin) and DPP3 (Dipeptidylpeptidase-3) to stratify patients most likely to benefit from treatment and exclude those with competing disease mechanisms.

Enibarcimab's mechanism is differentiated from neutralizing antibody approaches: rather than blocking ADM, it binds and traps ADM in the circulation while preserving its barrier-protective functionality, stabilizing endothelial cell junctions and reducing vascular leakage. Clinical proof-of-concept was established in the AdrenOSS-2 Phase II trial of 301 patients conducted in Germany, Belgium, France, and the Netherlands, which demonstrated a >60% relative reduction in 28-day all-cause mortality versus placebo in the biomarker-defined subgroup and a sustained benefit over three months, with results published in journals including The Lancet, Journal of Critical Care, Shock, and BMJ Open. The company has also explored enibarcimab in an investigator-initiated Phase II COVID-19 trial at University Medical Center Eppendorf (UKE Hamburg) and identified acute decompensated heart failure as a potential follow-on indication.

Adrenomed is pre-revenue and its economics are tied to clinical and regulatory milestones rather than product sales. The company has raised approximately EUR 46 million in equity across a 2018 Series D (EUR 24 million) and 2020 Series E (EUR 22 million), both co-led by Wellington Partners and HBM Healthcare Investments, supplemented by EUR 7.4 million in non-dilutive BMBF funding in 2022 and backing from KfW, Brandenburg Kapital, Hinkel, and the DBI fund. Its go-to-market targets hospital intensive care units globally, with regulatory engagement aligned to both the U.S. FDA (Fast Track designation granted April 2024) and European EMA (positive Scientific Advice December 2021). The company is preparing for a pivotal Phase III trial (BOOST) with biomarker-guided registration design and, post-approval, intends to commercialize through standard pharmaceutical distribution to hospital pharmacies and ICU settings, supported by a companion bio-ADM diagnostic co-developed with sphingotec GmbH.

Name

Adrenomed

Legal name

AdrenoMed AG

Website

https://adrenomed.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Adrenomed AG is a privately-financed German clinical-stage biopharmaceutical company developing enibarcimab, a first-in-class non-neutralizing monoclonal antibody targeting Adrenomedullin to restore vascular integrity in septic shock patients using a biomarker-guided precision medicine approach.

Ownership category

akta.pro rank

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product revenue: Pre-revenue clinical-stage company. Enibarcimab is in late-stage clinical development for septic shock. Revenue will be generated from pharmaceutical product sales upon regulatory approval. The company is preparing for pivotal Phase III trial (BOOST) following positive FDA and EMA regulatory feedback.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Adrenomed is developing enibarcimab, a clinical-stage first-in-class non-neutralizing monoclonal antibody that binds and stabilizes Adrenomedullin (ADM) in circulation to restore and protect vascular integrity. The product targets critically ill patients with septic shock and other conditions driven by vascular leakage, with patient selection guided by a dual-biomarker (bio-ADM and DPP3) precision medicine approach. The company is currently pre-revenue and preparing for a pivotal Phase III (BOOST) trial after FDA Fast Track designation in April 2024.

Product overview

Adrenomed is a clinical-stage biopharmaceutical company developing a single lead product candidate: enibarcimab (INN, formerly Adrecizumab, HAM8101). This first-in-class monoclonal antibody targets Adrenomedullin to treat life-threatening conditions associated with loss of vascular integrity, with septic shock as the primary indication. The company employs a biomarker-guided precision medicine approach using bio-ADM (biologically active Adrenomedullin) and DPP3 (Dipeptidylpeptidase 3) to identify patients most likely to benefit from treatment. The product does not fit a traditional SaaS platform-plus-modules architecture; it is a biologic drug therapeutic.

Differentiator

Problem solved

Functional benefit

Products and services

• Enibarcimab (HAM8101, formerly Adrecizumab) A clinical-stage, first-in-class non-neutralizing monoclonal antibody targeting Adrenomedullin (ADM) that binds and stabilizes ADM in circulation to restore vascular integrity in critically ill patients with septic shock and other conditions associated with increased vascular leakage. Administered as a single dose and being developed with a biomarker-guided precision medicine approach using bio-ADM and DPP3. Targeted at hospitals, ICUs, and acute care providers treating septic shock patients.

Quantifiable outcome

• >60% relative reduction in 28-day mortality vs placebo in biomarker-defined (bio-ADM and DPP3) target population with sustained effect over 3 months
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• University Medical Center Eppendorf (UKE) HamburgcoreImplementation/ SI/ Consulting Partner · 11 April 2022UKE Hamburg is conducting an investigator-initiated Phase II clinical trial with Adrecizumab (enibarcimab) in hospitalized COVID-19 patients with elevated adrenomedullin levels and endothelial barrier dysfunction. Prof. Dr. med. Stefan Kluge, Director of Department of Intensive Care Medicine at UKE, is leading the study.
• sphingotec GmbHcoreStrategic or Co-development PartnerStrategic partnership for biomarker development and diagnostics. sphingotec developed sphingotest bio-ADM for measuring biologically active Adrenomedullin and co-hosts international scientific symposiums on vascular integrity with Adrenomed. Both companies founded by Dr. Andreas Bergmann. bio-ADM biomarker used for patient stratification in AdrenOSS-2 and upcoming pivotal trials. sphingotec is developing point-of-care solution on Nexus IB10 platform for bio-ADM measurement.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Inotrem: Inotrem is a clinical-stage biotech developing nangibotide, a TREM-1 inhibitor for septic shock, pursuing a similar precision-medicine biomarker strategy targeting immune/vascular dysregulation in critically ill ICU patients.
• AM-Pharma: AM-Pharma is a clinical-stage biopharmaceutical company developing recombinant human alkaline phosphatase for the treatment of sepsis-associated acute kidney injury, targeting the same ICU/septic shock patient population as enibarcimab.
• InflaRx: InflaRx is a clinical-stage biopharmaceutical company developing vilobelimab, an anti-C5a monoclonal antibody for severe COVID-19, hidradenitis suppurativa, and other inflammatory indications, including sepsis-related applications.
• Atox Bio: Atox Bio is a late-stage clinical biotech developing AB103, a peptide therapeutic targeting the immune dysregulation pathway in necrotizing soft tissue infections and sepsis, with comparable septic shock development focus.
• Endpoint Health: Endpoint Health is a precision-medicine clinical-stage company developing targeted therapies for immune-driven critical illness including sepsis and septic shock, sharing the biomarker-guided patient selection paradigm.

Emerging players

• Enlivex Therapeutics: Enlivex Therapeutics is a clinical-stage company developing Allocetra, a cell therapy for sepsis and other inflammatory conditions, representing an alternative immunomodulatory approach to septic shock treatment.
• CytoDyn: CytoDyn is a clinical-stage biotechnology company that has investigated leronlimab (anti-CCR5 mAb) in sepsis-related indications, representing a comparable small-cap clinical-stage sepsis therapeutics developer.

Others

• sphingotec GmbH: sphingotec is a diagnostics company developing the bio-ADM biomarker assay used in Adrenomed's patient stratification; co-founded by Adrenomed's co-founder, making it a strategic ecosystem partner and supplier of the companion diagnostic.
• Adrenomed's sphingotest bio-ADM diagnostic: The bio-ADM (biologically active Adrenomedullin) assay from sphingotec is the diagnostic companion that stratifies septic shock patients for enibarcimab treatment; it is the enabling technology for Adrenomed's precision-medicine approach.

Broad incumbents

• Shionogi: Shionogi is a Japanese pharmaceutical company with established anti-infectives franchise (including cefiderocol) and active sepsis/critical-care portfolio, representing a potential large-pharma acquirer or commercial partner for enibarcimab.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/adrenomed
• LinkedInlinkedin.com/company/adrenomed-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adrenomed